Biotechnology News and Research

RSS

Janssen files abiraterone acetate NDS with Health Canada for metastatic, advanced prostate cancer

Janssen Inc. has filed a New Drug Submission (NDS) to Health Canada for the investigational drug abiraterone acetate administered with prednisone for the treatment of metastatic, advanced prostate cancer in patients who have received prior chemotherapy containing a taxane. Submissions for abiraterone acetate have also been filed with health authorities in the United States and Europe.

23 Dec 2010

HPV chemicals cause harm to human health, environment

Every hour, an enormous quantity and variety of manmade chemicals, having reached the end of their useful lifespan, flood into wastewater treatment plants. These large-scale processing facilities, however, are designed only to remove nutrients, turbidity and oxygen-depleting human waste, and not the multitude of chemicals put to residential, institutional, commercial and industrial use.

23 Dec 2010

Santen files IND for Clinical Data's ATL313 for primary open angle glaucoma and ocular hypertension

Clinical Data, Inc., today announced that Santen Pharmaceutical Co., Ltd., has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for Clinical Data's highly selective adenosine A2A agonist, ATL313, for the indication of primary open angle glaucoma and ocular hypertension.

From Santen Pharmaceutical Co., Ltd. 23 Dec 2010

Procognia grants Euro-Diagnostica license to provide diagnostic services for gastric cancer

Procognia is proud to announce that yesterday it signed a binding memorandum of understanding with Euro-Diagnostica (ED), a European diagnostic company that currently operates in the Scandinavian and Benelux markets, and is expected to expand its activity into other markets which may include Germany, Austria, Switzerland, and the UK in the near future.

23 Dec 2010

Discovery highlights potential to combat HIV/AIDS

Researchers at the University of Minnesota have discovered how HIV binds to and destroys a specific human antiviral protein called APOBEC3F. The results suggest that a simple chemical change can convert APOBEC3F to a more effective antiviral agent and that shielding of a common feature shared by related proteins may yield a similar outcome.

23 Dec 2010

BioTime enters MTA with UC to make research-grade hES cell lines

BioTime, Inc. today announced a material transfer agreement (MTA) with the University of California (UC) system to make five research-grade human embryonic stem (hES) cell lines available to UC system researchers. These lines are genetically identical to a bank of GMP-compliant hES cell lines that will be made available to California-based researchers under a recent agreement between BioTime and the California Institute for Regenerative Medicine (CIRM).

23 Dec 2010

Myrexis commences Azixa controlled two-arm Phase 2b clinical study in GBM

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it has initiated a controlled two-arm Phase 2b clinical study of Azixa (verubulin) as a front-line treatment for glioblastoma multiforme (GBM).

23 Dec 2010

Medicago completes first part of H5N1 vaccine Phase II trial

Medicago, a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that the last dose of vaccine has been administered completing the first part of the Company's Phase II human clinical trial with its H5N1 Avian Influenza vaccine.

23 Dec 2010

Enrollment begins in Phase 2 trial of RegeneRx’s RGN-259 in dry eye associated with graft vs. host disease

RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.

23 Dec 2010

Researchers identify class of drugs that can promote RBC formation in anemic patients

By determining how corticosteroids act to promote red blood cell progenitor formation, Whitehead Institute researchers have identified a class of drugs that may be beneficial in anemias, including those resulting from trauma, sepsis, malaria, kidney dialysis, and chemotherapy.

22 Dec 2010

Seaside purchases additional $2.5M of NanoViricides' Series B Convertible Preferred Stock

NanoViricides, Inc., announced today that it had consummated a closing with Seaside 88, LP ("Seaside"), a Florida limited partnership, on Seaside's purchase of an additional $2.5M of the Company's Series B Convertible Preferred Stock. Seaside has financed several leading-edge bio-pharma companies, including Cytori Therapeutics, Inc., Generex Biotechnology Corporation, and NovaDel Pharma, Inc. among others.

22 Dec 2010

USPTO terminates interference proceeding in favor of PDL's '089 Patent

PDL BioPharma, Inc. today announced that on December 15, 2010, the U.S. Patent and Trademark Office (the PTO) terminated its interference proceeding between certain claims of the Company's Queen et al., U.S. Patent No. 5,585,089, (the '089 Patent) and certain pending claims of Adair et al., U.S. Application No. 08/846,658, (the '658 Application) in favor of the Company's '089 Patent.

22 Dec 2010

BioCryst commences BCX4208/allopurinol combination Phase 2b study in gout patients

BioCryst Pharmaceuticals, Inc. announced the initiation of a Phase 2b study of BCX4208 as add-on therapy in gout patients who have not responded to allopurinol therapy alone.

22 Dec 2010

Global Business Forum on health care at University of Miami

The University of Miami will bring together some of the most influential leaders in business and government, along with hundreds of professionals from across industries, Jan. 12 - 14, 2011 for a Global Business Forum entitled "The Business of Health Care: Defining the Future."

22 Dec 2010

Vertex announces modification of telaprevir and VX-222 combination Phase 2 trial for treatment of HCV

Vertex Pharmaceuticals Incorporated today announced a modification of its Phase 2 clinical trial evaluating 12-week, response-guided regimens of its lead investigational hepatitis C virus (HCV) protease inhibitor, telaprevir, in combination with its lead investigational HCV polymerase inhibitor, VX-222.

22 Dec 2010

Researchers receive $100,000 NFL grant to study tissue engineering for spinal injuries

Researchers from Cornell University and Weill Cornell Medical College have been awarded $100,000 by NFL Charities, the charitable foundation of the National Football League owners, to research tissue engineering for spinal injuries.

22 Dec 2010

Biogen Idec, Elan propose updated product labeling for TYSABRI to FDA and EMA

Biogen Idec and Elan Corporation, plc announced that the companies have submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) and a Type II Variation to the European Medicines Agency (EMA) to request review and approval to update the respective TYSABRI Prescribing Information and Summary of Product Characteristics.

22 Dec 2010

New online tool helps scientists to find gene promoters

Researchers at The Wistar Institute announce the release of an online tool that will help scientists find "gene promoters"—regions along a DNA strand that tell a cell's transcription machinery where to start reading in order to create a particular protein.

22 Dec 2010

Amorcyte reports AMR-001 phase I trial results in heart attack patients

The American Heart Journal today reported results of a clinical trial evaluating Amorcyte, lead product candidate, AMR-001 for the treatment of damaged heart muscle following acute myocardial infarction.

22 Dec 2010

Pregnant women veterans face increase risk of mental health problems

Pregnancy among women veterans who served in Iraq and Afghanistan appears to increase their risk for mental health problems such as depression, anxiety, and post-traumatic stress disorder, according to a study published in Journal of Women's Health, a peer-reviewed journal published by Mary Ann Liebert, Inc. The paper is available free online.

22 Dec 2010

Biotechnology News and Research

Janssen files abiraterone acetate NDS with Health Canada for metastatic, advanced prostate cancer

HPV chemicals cause harm to human health, environment

Santen files IND for Clinical Data's ATL313 for primary open angle glaucoma and ocular hypertension

Procognia grants Euro-Diagnostica license to provide diagnostic services for gastric cancer

Discovery highlights potential to combat HIV/AIDS

BioTime enters MTA with UC to make research-grade hES cell lines

Myrexis commences Azixa controlled two-arm Phase 2b clinical study in GBM

Medicago completes first part of H5N1 vaccine Phase II trial

Enrollment begins in Phase 2 trial of RegeneRx’s RGN-259 in dry eye associated with graft vs. host disease

Researchers identify class of drugs that can promote RBC formation in anemic patients

Seaside purchases additional $2.5M of NanoViricides' Series B Convertible Preferred Stock

USPTO terminates interference proceeding in favor of PDL's '089 Patent

BioCryst commences BCX4208/allopurinol combination Phase 2b study in gout patients

Global Business Forum on health care at University of Miami

Vertex announces modification of telaprevir and VX-222 combination Phase 2 trial for treatment of HCV

Researchers receive $100,000 NFL grant to study tissue engineering for spinal injuries

Biogen Idec, Elan propose updated product labeling for TYSABRI to FDA and EMA

New online tool helps scientists to find gene promoters

Amorcyte reports AMR-001 phase I trial results in heart attack patients

Pregnant women veterans face increase risk of mental health problems

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News